These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26447374)

  • 1. 18F-FDG-PET/CT in the Staging and Management of Melanoma: A Prospective Multicenter Ontario PET Registry Study.
    Singnurkar A; Wang J; Joshua AM; Langer DL; Metser U
    Clin Nucl Med; 2016 Mar; 41(3):189-93. PubMed ID: 26447374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma.
    Schüle SC; Eigentler TK; Garbe C; la Fougère C; Nikolaou K; Pfannenberg C
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):482-8. PubMed ID: 26384681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Metser U; Dudebout J; Baetz T; Hodgson DC; Langer DL; MacCrostie P; Mak V; Tau N
    Cancer; 2017 Aug; 123(15):2860-2866. PubMed ID: 28295218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer.
    You JJ; Wong RK; Darling G; Gulenchyn K; Urbain JL; Evans WK
    J Thorac Oncol; 2013 Dec; 8(12):1563-9. PubMed ID: 24389439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
    Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
    J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
    Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS
    Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.
    Cachin F; Miot-Noirault E; Gillet B; Isnardi V; Labeille B; Payoux P; Meyer N; Cammilleri S; Gaudy C; Razzouk-Cadet M; Lacour JP; Granel-Brocard F; Tychyj C; Benbouzid F; Grange JD; Baulieu F; Kelly A; Merlin C; Mestas D; Gachon F; Chezal JM; Degoul F; D'Incan M
    J Nucl Med; 2014 Jan; 55(1):15-22. PubMed ID: 24263087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
    Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
    Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
    Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of
    Forschner A; Olthof SC; Gückel B; Martus P; Vach W; la Fougère C; Nikolaou K; Keim U; Eigentler TK; Garbe C; Pfannenberg C
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1312-1318. PubMed ID: 28315947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
    Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC
    Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/Contrast-Enhanced CT for Initial Staging and Strategic Treatment of Non-Small Cell Lung Cancer: A Prospective Study.
    Promteangtrong C; Kunawudhi A; Phadungrerk R; Iamsa-art C; Chotipanich C
    J Med Assoc Thai; 2015 Oct; 98(10):1010-8. PubMed ID: 26638593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.
    Barber TW; Duong CP; Leong T; Bressel M; Drummond EG; Hicks RJ
    J Nucl Med; 2012 Jun; 53(6):864-71. PubMed ID: 22582047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of FDG-PET in the assessment of survival prognosis in melanoma.
    Pleiss C; Risse JH; Biersack HJ; Bender H
    Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
    Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
    J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.